Prosecution Insights
Last updated: October 25, 2026

Olson and Cepuritis, Ltd.

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials

12 pending office actions • 9 clients • 12 examiners • 12 art units • 0 of 12 (0%) have an AI response strategy ready

Analysis

Olson & Cepuritis, LTD. has 13 pending office actions in Chemistry & Materials and 1554 career applications. Its resolved allowance rate is 79.15%, with an average of 2.77 office actions per allowance.

The application history supplies context for interpreting the current docket and resolved outcomes. The action average indicates recurring examination activity in allowed matters, so practitioners should connect amendment decisions to the specific claim and evidentiary record in each active file.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=1554 apps, methodology: how we score firms)

79.2%
Allowance Rate
n=1554
+0.50σ
Allowance Rate (norm)
n=1554
2.8
OAs to Allowance
n=1048
-0.55σ
OAs to Allow (norm)
n=1048
1062 days
Time to Allowance
n=1048
+10.6pp
Interview Lift
n=1554
13.8%
RCE Rate
n=1554
3.2%
Appeal Rate
n=1554

Rejection Performance (% of received rejections ultimately overcome)

87.1%
§101 Overcome
n=62
76.2%
§102 Overcome
n=365
74.4%
§103 Overcome
n=601
78.3%
§112 Overcome
n=534

Specialization & Scale

A61K, A61P, C07K
Top CPC Subclasses
19%
Top-3 CPC Share
n=1554
5
Practitioners
n=1554
310.8
Apps / Practitioner
n=1554

Portfolio Summary

12
Total Pending OAs
9
Non-Final OAs
3
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (50%)
5
Medium (42%)
1
Easy (8%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only4 (33%)
§102 only1 (8%)
Double-patenting only1 (8%)
Multi-statute (no §101)6 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

10
Life Sciences
83% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
17% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
PENG, BO JOSEPH 1 69.5% +13.6%
AYUB, HINA F 1 85.0% +17.2%
ROCHELLE, CIERRA MARIE 1 100.0% +0.0%
DEKARSKE, MADELINE MCGUIRE 1 20.0% +50.0%
ORJI, CALEB UCHECHUKWU 1 — —
TAKEUCHI, YOSHITOSHI 1 66.7% +24.2%
CABRAL, ROBERT S 1 62.8% +32.3%
LEFF, STEVEN N 1 41.4% +8.4%
HOLTZCLAW, MICHAEL T. 1 78.0% +15.5%
SEIFU, LESSANEWORK T 1 79.2% +1.3%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18743417 CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT ROCHELLE, CIERRA MARIE —

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18014027 METHOD AND DEVICE FOR RECYCLING WASTE MATERIALS CONTAINING VALUABLE METALS SEIFU, LESSANEWORK T 14d
19380575 ASYMMETRIC MARKER FOR DEPTH-SURFACE IMAGING PENG, BO JOSEPH —
19089433 LASER IMAGING AND RAMAN SCATTERING APPARATUS AND METHOD AYUB, HINA F —
18677013 COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS DEKARSKE, MADELINE MCGUIRE —
18437163 THIN FILM METAL AND METAL OXIDE ANODES FOR RECHARGEABLE BATTERIES ORJI, CALEB UCHECHUKWU —
18408979 Disordered Rock-Salt Cathode Materials with Lithiated Spinel Character TAKEUCHI, YOSHITOSHI —
18240743 NANOPARTICLE CANCER THERAPY CABRAL, ROBERT S —

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18113956 SURGICAL LASER FIBERS AND METHOD FOR MAKING SURGICAL LASER FIBERS HAVING AN ATRAUMATIC DISTAL END HOLTZCLAW, MICHAEL T. 19d
19380575 ASYMMETRIC MARKER FOR DEPTH-SURFACE IMAGING PENG, BO JOSEPH —
19089433 LASER IMAGING AND RAMAN SCATTERING APPARATUS AND METHOD AYUB, HINA F —
18677013 COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS DEKARSKE, MADELINE MCGUIRE —
18408979 Disordered Rock-Salt Cathode Materials with Lithiated Spinel Character TAKEUCHI, YOSHITOSHI —
18240743 NANOPARTICLE CANCER THERAPY CABRAL, ROBERT S —

Client Portfolio (9 clients)

Top Art Units

Art UnitApps
37971
17171
16271
16221
17131
17231
16181
17921
37961
17741

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19380575 ASYMMETRIC MARKER FOR DEPTH-SURFACE IMAGING Dermus Kft PENG, BO JOSEPH 3797 §102§103§112 Non-Final OA — Pending Nov 05, 2025
19089433 LASER IMAGING AND RAMAN SCATTERING APPARATUS AND METHOD UChicago Argonne, LLC AYUB, HINA F 1717 §103§112 Non-Final OA — Pending Mar 25, 2025
18743417 CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT Vivoryon Therapeutics N.V. ROCHELLE, CIERRA MARIE 1627 DP Non-Final OA — Pending Jun 14, 2024
18677013 COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS Papillex Inc. DEKARSKE, MADELINE MCGUIRE 1622 §103 Non-Final OA — Pending May 29, 2024
18437163 THIN FILM METAL AND METAL OXIDE ANODES FOR RECHARGEABLE BATTERIES UChicago Argonne, LLC ORJI, CALEB UCHECHUKWU 1713 §103§112 Non-Final OA — Pending Feb 08, 2024
18408979 Disordered Rock-Salt Cathode Materials with Lithiated Spinel Character UChicago Argonne, LLC TAKEUCHI, YOSHITOSHI 1723 §103§112 Non-Final OA — Pending Jan 10, 2024
18240743 NANOPARTICLE CANCER THERAPY UNIVERSITY OF SOUTH AUSTRALIA CABRAL, ROBERT S 1618 §102§103§112 Non-Final OA — Pending Aug 31, 2023
18236632 WEIGHABLE INDUCTION COOKER AND CONTROL METHOD THEREOF Jiangmen Yishan Metal Products Co., Ltd. LEFF, STEVEN N 1792 §103 Non-Final OA — Pending Aug 22, 2023
18113956 SURGICAL LASER FIBERS AND METHOD FOR MAKING SURGICAL LASER FIBERS HAVING AN ATRAUMATIC DISTAL END Laser Peripherals, LLC HOLTZCLAW, MICHAEL T. 3796 §103 Non-Final OA 19d Pending Feb 24, 2023
18014027 METHOD AND DEVICE FOR RECYCLING WASTE MATERIALS CONTAINING VALUABLE METALS Aura Technologie GmbH SEIFU, LESSANEWORK T 1774 §103§112 Final Rejection 14d Pending Dec 30, 2022
17879468 LITHIUM ION BATTERY RECYCLING PROCESS UTILIZING MAGNETIC SEPARATION OF ELECTRODE MATERIALS UChicago Argonne, LLC MARTIN, ANGELA J 1727 §103 Final Rejection 202d overdue Pending Aug 02, 2022
17826660 SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF The Scripps Research Institute OTTON, ALICIA L 1699 §102 Final Rejection — Pending May 27, 2022

Managing Olson and Cepuritis, Ltd.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Olson and Cepuritis, Ltd.'s patent allowance rate?

79.2% of resolved applications prosecuted by Olson and Cepuritis, Ltd. were allowed, across 1,554 applications in USPTO records.

How many office actions does Olson and Cepuritis, Ltd. average before allowance?

2.77 office actions per allowed application on average.

How many pending office actions does Olson and Cepuritis, Ltd. have?

12 pending office actions as of October 2026, for 9 clients, before 12 examiners in 12 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month